You are here: Home » Companies » News
Business Standard

Glenmark gets tentative nod from USFDA to market prostate cancer drug

The approved product is a generic version of Janssen Biotech Inc's Zytiga tablets

Topics
Usfda  |  Prostate Cancer  |  Glenmark Pharmaceuticals

Press Trust of India  |  New Delhi 

Glenmark
Photo: iStock

has received tentative nod from the US health regulator for Abiraterone Acetate tablets, used in the treatment of

Inc USA has been granted tentative approval by the United States Food and Drug Administration for Abiraterone Acetate tablets USP in the strength of 250 mg, the company said in a BSE filing on Wednesday.

The approved product is a generic version of Janssen Biotech Inc's Zytiga tablets.

Quoting IQVIA sales data for the 12-month period ended November 2018, said, Zytiga tablets 250 mg market achieved annual sales of approximately $1.3 billion.

The company's current portfolio consists of 148 products authorised for distribution in the US market and 54 abbreviated new drug applications (ANDAs) pending approval with the

Shares of Glenmark Pharmaceuticals were trading 1.17 per cent lower at Rs 648.45 apiece on the BSE.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 23 2019. 11:30 IST
RECOMMENDED FOR YOU
.